Diabetes

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Pharmacists are in a strong position to identify the early warning signs of diabetes because they are often the most accessible and frequently visited members of the health care team.

The introduction of a biosimilar insulin could result in major shifts in the accessibility and affordability of insulin for all patients.

Depending on the patient needs, the prescriber can prescribe one or both types of insulin.

Antidepressants may lower the risk of death and serious complications from diabetes for patients with both diabetes and depression, according to a study published in the Journal of Clinical Endocrinology & Metabolism.

Though the benefits of continuous glucose monitoring for patients with diabetes has been previously demonstrated, the investigators said that these benefits have only been well-established for patients with type 1 diabetes or patients with type 2 diabetes treated with multiple daily insulin injections.

Patients on metformin should check their vitamin B12 levels on regular basis to make sure it is at normal range.

Patients at risk for diabetes should try to focus on adhering to their medications, diet and exercise to reduce their blood sugars, which will decrease their A1C levels.

The investigators also predicted that the increase in indications of novel diabetes treatments and their increased use is likely to result in greater expense.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.

Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.

APhA offers intensive certificate course on integrating education and management into practice.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Ten quiz questions to assess your knowledge on common diabetes treatments.

Below a certain GFR, clinically significant reductions in plasma glucose cannot be achieved with sodium-glucose transport protein 2 inhibitors.

How should pharmacists manage a patient with diabetes on metformin with GFR below 30?

The shift to telemedicine for patient care for individuals with diabetes showed little negative impact on the metabolic health of these patients.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed what changes would be necessary to continue providing quality virtual health care to patients with diabetes.

The FDA has approved finerenone for the treatment of adult patients with chronic kidney disease associated with type 2 diabetes.

Early intervention by pharmacists can help stave off condition's serious consequences.

Individuals with at least one inactive copy of the gene have lower BMIs and, on average, face a 54% lower risk of obesity than individuals without the mutations.

Similar effects were seen both with and without an SGLT2 inhibitor, according to investigators.

The approval marks the first nonsteroidal mineralocorticoid receptor antagonist proven to significantly slow chronic kidney disease progression and reduce cardiovascular risk in individuals with chronic kidney disease associated with type 2 diabetes.

No significant differences were found in blood pressure, blood sugar levels, or kidney function when comparing both medications among patients with type 2 diabetes.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed the changes made to health care practices in light of the COVID-19 pandemic that she would like to see remain in place in the future.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.

Mary Reed, DrPH, research scientist at Kaiser Permanente, discussed how COVID-19 forced health systems to shift primarily to telehealth, and the impact this had on patients with diabetes.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.

Patients with diabetes treated with liraglutide also saw more weight loss compared with patients in the other arms of the study.